You are here

  • Home
  • Archive
  • Volume 48, Issue 4
  • Colorectal cancer susceptibility loci on chromosome 8q23.3 and 11q23.1 as modifiers for disease expression in lynch syndrome

Article Text

Article menu
Download PDFPDF
Short report
Colorectal cancer susceptibility loci on chromosome 8q23.3 and 11q23.1 as modifiers for disease expression in lynch syndrome
  1. Bente A Talseth-Palmer1,2,
  2. Ingvild S Brenne2,3,
  3. Katie A Ashton1,2,
  4. Tiffany-Jane Evans1,2,
  5. Mary McPhillips4,
  6. Claire Groombridge5,
  7. Janina Suchy6,
  8. Grzegorz Kurzawski6,
  9. Allan Spigelman7,
  10. Jan Lubinski6,
  11. Rodney J Scott1,2,4
  1. 1School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, Australia
  2. 2Hunter Medical Research Institute, John Hunter Hospital, Newcastle, Australia
  3. 3Department of Pharmacology, Institute of Pharmacy, Faculty of Medicine, University of Tromsø, Norway
  4. 4Hunter Area Pathology Service, Hunter New England Area Health, Newcastle, Australia
  5. 5Hunter Family Cancer Service, Hunter New England Area Health, Newcastle, Australia
  6. 6International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin, Poland
  7. 7University of NSW, St Vincent's Hospital Clinical School, Sydney, Australia
  1. Correspondence to Dr Bente A Talseth-Palmer, HMRI, Room 3642, Level 3, John Hunter Hospital, Lookout Rd, New Lambton Heights, NSW 2305, Australia; bente.talseth-palmer{at}newcastle.edu.au

Abstract

Objective Recently, six colorectal cancer (CRC) susceptibility loci have been identified, and two single-nucleotide polymorphisms (SNPs)—rs16892766 (8q23.3) and rs3802842 (11q23.1)—from two of these regions have been found to be significantly associated with an increased CRC risk in patients with Lynch syndrome. The objective of this study was to genotype nine SNPs within these six loci to confirm previous findings and investigate whether they act as modifiers of disease risk in patients with Lynch syndrome.

Design The patient cohort consisted of 684 mutation-positive patients with Lynch syndrome from 298 Australian and Polish families. Nine SNPs were genotyped: rs16892766 (8q23.3), rs7014346 and rs6983267 (8q24.21), rs10795668 (10p14), rs3802842 (11q23.1), rs10318 and rs4779584 (15q13.3), and rs4939827 and rs4464148 (18q21.1). The data were analysed to investigate possible associations between the presence of variant alleles and the risk of developing disease.

Results An association between SNP rs3802842 on chromosome 11q23.1 and rs16892766 on chromosome 8q23.3 and the risk of developing CRC and age of diagnosis was found in MLH1 mutation carriers. Female MLH1 mutation carriers harbouring the homozygous variant genotype for SNP rs3802842 have the highest risk of developing CRC. When the number of risk alleles for the two SNPs combined was analysed, a difference of 24 years was detected between individuals carrying three risk alleles and those carrying no risk alleles.

Conclusion The authors were able to replicate the association between the CRC susceptibility loci on chromosomes 8q23.3 and 11q23 and the risk of developing CRC in patients with Lynch syndrome, but the association could only be detected in MLH1 mutation carriers in this study.

  • CRC susceptibility loci
  • 8q23.3
  • 11q23.1
  • lynch syndrome
  • gastroenterology
  • molecular genetics
  • cancer
  • colon

https://doi.org/10.1136/jmg.2010.079962

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding This study was supported by grants from the Hunter Medical Research Institute and the Gladys M Brawn Memorial Fund through the University of Newcastle.

    • Competing interests None.

    • Ethics approval This study was conducted with the approval of the Hunter Area Research Ethics Committee (Australia), University of Newcastle Human Research Ethics Committee (Australia) and the ethics committee of the Pomeranian Academy of Medicine (Poland).

    • Provenance and peer review Not commissioned; externally peer reviewed.